Clinical trials
Lymphoma, B-Cell clinical trials
Below are recruiting lymphoma, b-cell clinical trials, each written for real people, not researchers. We’re tracking 534 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06994169Recruiting
Glofitamab treatment study for relapsed DLBCL
This study looks at how well glofitamab works in real-world patients with a type of lymphoma that has come back or not responded to treatment. It includes adults who have already received obinutuzumab and at least one dose of glofitamab in a special access program.
ArgenteuilAges 18 years+ - NCT06996132RecruitingPhase 2
Combination treatment for aggressive B-cell lymphoma that has returned
This trial tests a new combination approach for people whose aggressive B-cell lymphoma has come back or not responded to treatment. It uses a bispecific antibody (a type of drug that helps immune cells attack cancer cells) followed by CAR-T cell therapy (reprogramming your own immune cells to find and kill cancer), sometimes with a stem cell transplant.
TianjinAges 18–65 - NCT06985576Enrolling by invitation
Long-term safety follow-up for GF-CART01
This study is a long-term follow-up for people who have already received the GF-CART01 treatment in a previous study. It checks how safe the treatment stays over time and how long the effects last.
TaipeiAges Any age - NCT06987916RecruitingPhase 1/Phase 2
Testing new immune cell therapy for B-cell lymphoma
This trial tests a new immune cell treatment (called U01 or ssCART-19) for people with B-cell lymphoma that has come back or not responded to other treatments. It aims to see if the therapy is safe and effective.
Shanghai, Shanghai MunicipalityAges 2–75 - NCT06986174RecruitingPhase 2
Pacritinib for relapsed or refractory Waldenström macroglobulinemia
This trial tests a pill called pacritinib for people with Waldenström macroglobulinemia that has come back or stopped responding to other treatments. The goal is to see if pacritinib can help control the disease by blocking certain proteins that cancer cells need to grow.
Boston, MassachusettsAges 18 years+ - NCT06414148RecruitingPhase 2
Epcoritamab with or without lenalidomide and rituximab after CAR T
This trial tests whether adding a drug called epcoritamab (with or without two other drugs, lenalidomide and rituximab) can help people with large B-cell lymphoma whose cancer was still detectable after CAR T-cell therapy. It aims to stop the cancer from coming back.
Camperdown, New South WalesAges 16 years+ - NCT06742502RecruitingPhase 2
Immunotherapy plus R-CHOP for untreated PMBCL
This trial is testing a new combination of immunotherapy (sintilimab and rituximab) followed by standard chemotherapy (R-CHOP) for people with untreated primary mediastinal B-cell lymphoma (PMBCL). It aims to see if this approach can improve outcomes for this specific type of lymphoma.
Fuzhou, FujianAges 18–75 - NCT05541341Recruiting
Tisagenlecleucel outcomes study in relapsed B-cell blood cancers
This study looks at how safe and effective tisagenlecleucel is for people in Brazil who have certain B-cell blood cancers that came back or did not respond to treatment. You may be included if you already received tisagenlecleucel outside a research study and can consent to share your medical data.
Minas Gerais, Belo HorizonteAges birth–100 years - NCT06980116RecruitingPhase 1
Finding the right dose of EXS73565 for relapsed B-cell cancers
This study tests a new oral medication (EXS73565) for people with B-cell blood cancers that came back or didn't respond to standard treatments. It aims to find the best dose and check if it's safe and helpful.
TbilisiAges 18 years+ - NCT06977711RecruitingPhase 1
Testing a new drug combo for high-risk DLBCL
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
San Antonio, TexasAges 18 years+ - NCT06976437RecruitingEarly Phase 1
Testing donor CAR-T cells for B-cell blood cancers
This trial tests a new treatment using specially engineered immune cells from a healthy donor to fight certain B-cell blood cancers that have come back or not responded to standard therapy. It aims to see if these cells can safely help patients achieve remission.
Zhenjiang, JiangsuAges 18 years+ - NCT06940960Recruiting
JY231 cell therapy for relapsed B-cell lymphoma or leukemia
This trial tests a new cell therapy (JY231) for people whose B-cell lymphoma or leukemia (B-ALL) has returned or not responded to earlier treatments. The therapy uses your own T cells, modified to target the CD19 marker on cancer cells.
Guangzhou, GuangdongAges 12–75 - NCT06954805RecruitingPhase 2
Study of ctDNA in PTLD after transplant
This trial looks at a blood test (ctDNA) to track post-transplant lymphoproliferative disorder (PTLD). It tests how well ctDNA measures treatment response and may help guide future care.
Stanford, CaliforniaAges 15 years+ - NCT06948981RecruitingPhase 1/Phase 2
GT719 Injection for Relapsed CD19+ B-cell Cancers
This trial tests a new injection called GT719 for adults with B-cell cancers that have come back or not responded to treatment. The cancer cells must have a marker called CD19. The study aims to see if the treatment is safe and works.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT05388695RecruitingPhase 1
Testing dual-target CAR T cells for B-cell blood cancers
This Phase 1 study tests CAR T cells designed to attack B-cell blood cancers using two targets (CD19 and CD20/CD22). It may help people whose cancer has come back or not responded to standard treatments, but it is mainly to check safety and early effectiveness.
Wuhan, HubeiAges 18–70 - NCT06931652RecruitingPhase 2
Epcoritamab with lenalidomide and rituximab for CNS lymphoma
This trial tests a new combination of drugs—epcoritamab, lenalidomide, and rituximab—for people with primary central nervous system lymphoma (PCNSL) that has come back or not responded to treatment. The goal is to see if this three-drug therapy can help control the cancer.
BordeauxAges 18 years+ - NCT06919939RecruitingPhase 2
Epcoritamab and Loncastuximab for relapsed large B-cell lymphoma
This trial tests a combination of two targeted drugs (epcoritamab and loncastuximab tesirine) for people with large B-cell lymphoma that has come back or not responded to prior treatment. The goal is to see if this combination can shrink tumors and improve outcomes.
Miami, FloridaAges 18 years+ - NCT06905509RecruitingPhase 2
Epcoritamab with chemo and stem cell transplant for large B-cell lymphoma
This trial tests adding epcoritamab (an immune therapy that helps your body fight cancer) to standard chemotherapy followed by a stem cell transplant. It is for people with large B-cell lymphoma that has come back or not responded to initial treatment.
Sacramento, CaliforniaAges 18 years+ - NCT06890884RecruitingPhase 2
Comparing two drug combos for untreated DLBCL
This trial tests a new drug, zilovertamab vedotin, added to standard chemo, compared with another approved drug combo for people with untreated DLBCL (a type of lymphoma). It aims to see which is more effective.
Mobile, AlabamaAges 18 years+ - NCT06898905Recruiting
Study of radiation therapy for lymphoma patients getting CAR T or bispecific antibody treatment
This study combines a special schedule of radiation therapy with new cancer treatments (CAR T cells or bispecific antibodies) for adults whose lymphoma has come back or not responded. The radiation is given in small doses twice a day to help the treatment work better.
New Haven, ConnecticutAges 18 years+ - NCT06880913RecruitingPhase 1/Phase 2
Dual CAR-T therapy for relapsed B-cell acute lymphoblastic leukemia
This trial tests a new type of CAR-T cell therapy that targets two markers (CD19 and CD22) on leukemia cells. It's for people whose B-cell acute lymphoblastic leukemia has come back or hasn't responded to other treatments.
Beijing, Beijing MunicipalityAges 12–65 - NCT06871007Enrolling by invitationPhase 1/Phase 2
Nivolumab with chemo for pediatric large B-cell lymphoma
This trial tests adding nivolumab (an immunotherapy drug) to a standard chemotherapy regimen for children with primary mediastinal large B-cell lymphoma. It may help improve outcomes for newly diagnosed patients.
MoscowAges Up to 18 years - NCT06879340RecruitingPhase 1
Testing a new CAR-T therapy for B-cell blood cancers
This study tests a new CAR-T cell therapy called DuoCAR20.19.22-D95 for people with certain blood cancers (like lymphoma and ALL) that have come back or haven't responded to multiple treatments. It aims to see if this therapy is safe and can help shrink or control the cancer.
Westwood, KansasAges 18 years+ - NCT06867536RecruitingPhase 2
Radiation plus glofitamab for relapsed large B-cell lymphoma with large tumors
This trial tests whether combining a short course of radiation with a targeted antibody drug (glofitamab) can help people with aggressive large B-cell lymphoma that came back after treatment, especially if they have bulky tumors. It aims to find a new option for hard-to-treat cases.
Wuhan, HubeiAges 18–75
Hear when a new Lymphoma, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lymphoma, b-cell?
- Yes. Clin2 currently lists 534 recruiting lymphoma, b-cell studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lymphoma, b-cell trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lymphoma, b-cell trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.